Merck & Company Inc (MRK)vsScynexis Inc (SCYX)
MRK
Merck & Company Inc
$132.93
+1.92%
HEALTHCARE · Cap: $316.14B
SCYX
Scynexis Inc
$4.81
-0.52%
HEALTHCARE · Cap: $299.50M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 323180% more annual revenue ($65.77B vs $20.34M). MRK leads profitability with a 13.6% profit margin vs -120.5%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
SCYX
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-60.9%
Fair Value
$81.38
Current Price
$132.93
$51.55 premium
Intrinsic value data unavailable for SCYX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 4.5B in free cash flow
Reasonable price relative to book value
Revenue surging 1809.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
ROE of 7.6% — below average capital efficiency
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -53.4% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : SCYX
The strongest argument for SCYX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 1809.0% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : SCYX
The primary concerns for SCYX are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while SCYX is a hypergrowth play — different risk/reward profiles.
SCYX carries more volatility with a beta of 1.10 — expect wider price swings.
SCYX is growing revenue faster at 1809.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 35/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Scynexis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
SCYNEXIS, Inc., a biotechnology company, offers therapies for the treatment of yeast infections in the United States. The company is headquartered in Jersey City, New Jersey.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?